The cycle of migraine: Patients' quality of life during and between migraine attacks

https://doi.org/10.1016/j.clinthera.2007.05.008Get rights and content

Abstract

Background:

Despite advances in therapy, the prevalence of migraine has remained constant over the past 17 years. The current diagnostic procedure for migraine does not take into account the entire cycle of migraine, which includes both the pain of the acute attack and the worry between attacks.

Objectives:

This review discusses the effects of migraine on health-related quality of life. The focus is on the impact of migraine between attacks and more successful clinical management of the complete cycle of migraine in both the neurology and primary care settings.

Methods:

A search of MEDLINE (January 1997–January 2007) was conducted to determine the impact of migraine on quality of life and the need for and use of migraine preventive treatment. The search terms were migraine prevention, migraine prophylaxis, bead-ache and quality of life, migraine disability, and head-ache disability. The inclusion of specific studies was based on subjective, comparative evaluation and standard levels of evidence. Older publications were included to provide a historical perspective.

Results:

Worry in expectation of the next migraine attack can have negative effects on the family and social lives and work productivity of patients with migraine. The benefits of preventive pharmacotherapy for migraine may be measured over time in terms of changes in the frequency of acute attacks, impact of acute treatment on headache recurrence within the next 24 hours, and reduction in overall functional impairment. Optimizing the acute treatment outcome and reducing the frequency of episodes may help alleviate the cycle of migraine. The clinical assessment of migraine should include multiple dimensions. Several questionnaires, such as the Migraine Disability Assessment and the 6-item Headache Impact Test, have been developed to help clinicians assess the dimensions of migraine. These questionnaires should be used in conjunction with open communication techniques that elicit any underlying worry associated with migraines. Preventive therapies that have been approved by the US Food and Drug Administration include the neurostabilizers divalproex sodium and topiramate, and the β-blockers timolol and propranolol. Despite not being approved for this indication, the antidepressant amitriptyline has shown levels of evidence of efficacy in preventing migraine in controlled trials similar to those for the approved medications.

Conclusion:

The assessment of whether patients with migraine may benefit from preventive therapy should include the use of open communication techniques to uncover possible impairment between attacks.

References (74)

  • LindeM. et al.

    Attitudes and burden of disease among self-considered migraineurs a nationwide populationbased survey in Sweden

    Cephalalgia

    (2004)
  • BrandesJ.L.

    Global trends in migraine care: Results from the MAZE survey

    CNS Drugs

    (2002)
  • WacogneC. et al.

    Stress, anxiety, depression and migraine

    Cephalalgia

    (2003)
  • DahlofC.G. et al.

    The burden of migraine to the individual sufferer: A review

    Eur J Neurol

    (1998)
  • EdmeadsJ. et al.

    Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: A Canadian population survey

    Cant Neurol Sci

    (1993)
  • DowsonA. et al.

    The UK Migraine Patient Survey: Quality of life and treatment

    Curr Med Res Opin

    (1999)
  • LiptonR.B. et al.

    The family impact of migraine: Population-based studies in the USA and UK

    Cephalalgia

    (2003)
  • HahnS.R. et al.

    Provider-patient migraine discussions: Results of American Migraine Communication Study (AMCS)

  • DiamondS. et al.

    Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention Study

    Headache

    (2007)
  • SilbersteinS.D. et al.

    Migraine preventive medication reduces resource utilization

    Headache

    (2003)
  • LiptonR.B. et al.

    Why headache treatment fails

    Neurology

    (2003)
  • OlesenJ. et al.

    New appendix criteria open for a broader concept of chronic migraine

    Cephalalgia

    (2006)
  • BigalM.E. et al.

    When migraine progresses: Transformed or chronic migraine

    Expert Rev Neurother

    (2006)
  • LiptonR.B. et al.

    The epidemiology of migraine

    Am J Med

    (2005)
  • MillerV.A.

    Misunderstood and misdiagnosed: The agony of migraine headache

    Adv Nurse Pract

    (2005)
  • SaadahH.A.

    Headache fear

    J Okla State Med Assoc

    (1997)
  • LiptonR.B. et al.

    Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and healthrelated quality of life

    Neurology

    (2005)
  • DahlofC.G. et al.

    Migraine patients experience poorer subjective well-being/quality of life even between attacks

    Cephalalgia

    (1995)
  • StronksD.L. et al.

    Interictal daily functioning in migraine

    Cephalalgia

    (2004)
  • BoardmanH.F. et al.

    Psychological, sleep, lifestyle, and comorbid associations with headache

    Headache

    (2005)
  • HurseyK.G. et al.

    Fear of pain in re-current headache sufferers

    Headache

    (1992)
  • ZeebergP. et al.

    Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness

    Cephalalgia

    (2006)
  • StronksD.L. et al.

    Personality traits and psychological reactions to mental stress of female migraine patients

    Cephalalgia

    (1999)
  • SheftellF.D. et al.

    Optimizing the diagnosis and treatment of migraine

    J Am Acad Nurse Pract

    (2005)
  • DahlofC.G.

    Measuring disability and quality of life in migraine

    Drugs Today (Barc)

    (2003)
  • StewartW. et al.

    Need for Care and Perceptions of MIDAS Among Headache Sufferers study

    CNS Drugs

    (2002)
  • BordiniC.A. et al.

    Effect of preventive treatment on health-related quality of life in episodic migraine

    J Headache Pain

    (2005)
  • Cited by (72)

    • Mitochondrial migraine; a prevalence, impact and treatment efficacy cohort study

      2020, Mitochondrion
      Citation Excerpt :

      Migraine is a common disorder characterized by pulsating moderate to severe headache which is associated with an assortment of additional symptoms including nausea and/or photophobia and phonophobia according to the International classification of Headache Disorders (ICHD-3) (“Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition,” 2018). Persistent interictal symptoms and the repeating migraine attacks are associated with ongoing interictal emotional and psychologic impairment (Freitag, 2007) and they can result in a decreased health related quality of life, social impact and increased disability (Kawata et al., 2017). Migraine affects ±12% of the studied Caucasian population (Goadsby, 2003).

    • Frovatriptan loaded hydroxy propyl methyl cellulose/treated chitosan based composite fast dissolving sublingual films for management of migraine

      2018, Journal of Drug Delivery Science and Technology
      Citation Excerpt :

      In migraine therapy, the effectiveness of a medication is assessed by measuring reduction in severity of cephalalgia from reasonable or intense pain to low or no pain after 2 h of administration of medication. Therefore, the drugs used for pain relief in migraine should have a quick onset of action [6,7]. Sublingual delivery of drug provides the most promising route for drugs requiring fast absorption and rapid onset of action consequently leading to enhanced bioavailability.

    • TPGS stabilized sublingual films of frovatriptan for the management of menstrual migraine: Formulation, design and antioxidant activity

      2017, Journal of Drug Delivery Science and Technology
      Citation Excerpt :

      However, the duration may vary from 4 to 72 h [4]. Thus the drugs with a quick onset of pharmacological effect are often preferred so as to resume the functional abilities of patient as soon as possible [5]. Sublingual administration offers a convenient route for systemic availability of drug showing advantage of direct entry into systemic circulation bypassing hepatic first pass effect [6].

    View all citing articles on Scopus
    View full text